CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 

Longeveron Inc 's Total Debt to Equity

LGVN's quarterly Total Debt to Equity and Total Debt, Equity growth




LGVN Total Debt to Equity (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change 10.22 % 19.19 % - - -
Y / Y Total Debt Change -9.59 % -9.33 % - - -
Total Debt to Equity MRQ 0.11 0.1 0.09 0.07 0.14
Overall Ranking # # # # #
Seq. Equity Change -16.22 % -14.36 % -8.4 % 67.7 % -9.4 %
Seq. Total Debt Change -4.66 % -4.45 % 15.55 % -14.11 % -4.38 %



Total Debt to Equity third quarter 2022 Comment
In Spite of the debt repayement of -4.66%, in III. Quarter ,Total Debt to Equity detoriated to 0.11, above company's average Total Debt to Equity.

Within Major Pharmaceutical Preparations industry Longeveron Inc achieved lowest Total Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. .

Explain Debt to Equity Ratio?
Where is LGVN most successful ?
Total Debt to Equity LGVN on the trailing twelve month basis
Total Debt to Equity third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Longeveron Inc 's Equity $ 25 Millions Visit LGVN's Balance sheet
Longeveron Inc 's Total Debt $ 3 Millions Visit LGVN's Balance sheet
Source of LGVN's Sales Visit LGVN's Sales by Geography


Cumulative Longeveron Inc 's Total Debt to Equity

LGVN's Total Debt to Equity for the trailling 12 Months

LGVN Total Debt to Equity

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth 10.22 % 19.19 % - - -
Y / Y Total Debt TTM Growth -9.59 % -9.33 % - - -
Total Debt to Equity TTM 0.09 0.09 0.1 0.1 0.13
Total Ranking TTM # 503 # 494 # 337 # 17 # 331
Seq. Equity TTM Growth -16.22 % -14.36 % -8.4 % 67.7 % -9.4 %
Seq. Total Debt TTM Growth -4.66 % -4.45 % 15.55 % -14.11 % -4.38 %


TTM Total Debt to Equity Comment
On the trailing twelve months basis Due to debt repayement of -4.66% Longeveron Inc has not changed Total Debt to Equity in the III. Quarter to 0.09, above Longeveron Inc 's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 36 other companies have achieved lower Total Debt to Equity than Longeveron Inc . While total ranking remained unchanged compare to previous quarter at no. 503.

Explain Debt to Equity Ratio?
Where is LGVN most successful ?
Total Debt to Equity LGVN on the trailing twelve month basis

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 37
Healthcare Sector # 119
Within the Market # 503


TTM Total Debt to Equity Statistics
High Average Low
0.01 0.01 0
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Total Debt to Equity in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquitySep 30 2022 MRQ Total DebtSep 30 2022 MRQ Equity
Apellis Pharmaceuticals Inc   0.30 $ 92.663  Millions$ 307.416  Millions
Acelrx Pharmaceuticals Inc  0.29 $ 7.886  Millions$ 27.226  Millions
Iterum Therapeutics Plc  0.29 $ 9.298  Millions$ 32.549  Millions
Organogenesis Holdings Inc   0.28 $ 72.604  Millions$ 256.328  Millions
Alkermes Plc   0.28 $ 293.904  Millions$ 1,042.854  Millions
Mersana Therapeutics inc   0.28 $ 24.853  Millions$ 90.229  Millions
Roivant Sciences Ltd   0.27 $ 411.812  Millions$ 1,514.149  Millions
Aytu Biopharma inc   0.27 $ 14.485  Millions$ 53.906  Millions
Accustem Sciences Inc   0.27 $ 0.212  Millions$ 0.798  Millions
Eagle Pharmaceuticals inc   0.26 $ 61.392  Millions$ 231.780  Millions
Gossamer Bio Inc   0.26 $ 14.834  Millions$ 56.351  Millions
Rhythm Pharmaceuticals inc   0.26 $ 72.961  Millions$ 281.195  Millions
Aptevo Therapeutics Inc   0.25 $ 3.910  Millions$ 15.762  Millions
Blueprint Medicines Corporation  0.25 $ 158.829  Millions$ 640.307  Millions
Uniqure N v   0.24 $ 102.394  Millions$ 421.170  Millions
Oncorus Inc   0.24 $ 19.257  Millions$ 79.996  Millions
Nabriva Therapeutics Plc  0.24 $ 6.132  Millions$ 25.623  Millions
Celularity Inc   0.24 $ 39.255  Millions$ 164.235  Millions
Biomarin Pharmaceutical Inc  0.24 $ 1,082.033  Millions$ 4,568.514  Millions
Savara Inc   0.22 $ 26.010  Millions$ 116.514  Millions
Capricor Therapeutics inc   0.22 $ 3.376  Millions$ 15.426  Millions
Agile Therapeutics Inc  0.21 $ 1.318  Millions$ 6.260  Millions
Liquidia Corporation  0.21 $ 19.741  Millions$ 95.034  Millions
Cue Biopharma Inc   0.20 $ 9.956  Millions$ 50.764  Millions
Iveric Bio Inc   0.18 $ 47.649  Millions$ 259.526  Millions
Frequency Therapeutics Inc   0.18 $ 15.000  Millions$ 81.973  Millions
Centessa Pharmaceuticals Plc  0.18 $ 68.200  Millions$ 372.921  Millions
United Therapeutics Corporation  0.18 $ 800.000  Millions$ 4,562.200  Millions
F star Therapeutics Inc   0.17 $ 9.840  Millions$ 56.938  Millions
Orgenesis Inc   0.17 $ 5.162  Millions$ 30.250  Millions

Date modified: 2022-11-16T07:45:10+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AIM's Profile

Stock Price

AIM's Financials

Business Description

Fundamentals

Charts & Quotes

AIM's News

Suppliers

AIM's Competitors

Customers & Markets

Economic Indicators

AIM's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071